
4D Molecular Therapeutics misses Q3 earnings estimates but beats revenue expectations again
4D Molecular Therapeutics reported a wider adjusted loss of $1.08 per share for Q3 2026, missing analyst expectations. However, the company's revenue reached $4.15 million, surpassing both estimates and last year's figures, continuing a trend of stro...





